Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Atezolizumab clinical trials

Also listed in trial records as RO5541267, MPDL3280A, BL-M14D1, RG7446, BL-M14D1 and Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL328OA, RG 7446, RO 5541267, L01XC
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 175 trials in our USA, Spain, Germany, France, Italy, China, South Korea, Canada, Australia, Israel, Belgium, UK, Taiwan, Poland, Japan, Netherlands, Mexico, Turkey, Switzerland, Brazil, Austria, Czechia, Singapore, Denmark, Portugal, Norway, Sweden, Egypt, India and Ireland registers that name Atezolizumab as an intervention. Synced 13 Nov 2026
175Current trials
70Recruiting now
106Lead sponsors
30Country registers
At a glance

Atezolizumab is named as an intervention in 175 current clinical trials in our USA, Spain, Germany, France, Italy, China, South Korea, Canada, Australia, Israel, Belgium, UK, Taiwan, Poland, Japan, Netherlands, Mexico, Turkey, Switzerland, Brazil, Austria, Czechia, Singapore, Denmark, Portugal, Norway, Sweden, Egypt, India and Ireland registers. 70 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Hoffmann-La Roche (21). The most-studied condition is Hepatocellular Carcinoma. The EU clinical trials register (CTIS) separately lists 5 authorised or ongoing trials, 1 with a site in Ireland.

Atezolizumab also has an approved-drug profile on this site (FDA label data): Tecentriq (Atezolizumab) →

Where Atezolizumab is approved

All regulators →

Of the three regulators tracked here, the first to approve Atezolizumab was the US, on 18 May 2016. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)
18 May 2016
Tecentriq
BLA761034 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
20 Sep 2017
Tecentriq
EMA product page
First centralised authorisation
CACanada (Health Canada)
12 Apr 2017
Tecentriq
Notice of Compliance 19156
First new-drug NOC
  • 2 EU safety letters (DHPC), latest: quality defect for RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq, 17 Aug 2023

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Atezolizumab

All medicines →
ENNHS England
Not dispensed in the community in England in the last 12 months under this name
Net ingredient cost, community prescriptions
USUS Medicaid
$75.3m
10,328 prescriptions in 2025 · Tecentriq
-17% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Atezolizumab works

All drug targets →
  • Programmed cell death 1 ligand 1 inhibitor Inhibitor
    Target: CD274 CD274 molecule
    ChEMBL only
Diseases it has been tested for in clinical trials, by furthest phase
  • Venous thrombosisPhase 3
  • Bladder transitional cell carcinomaPhase 3
  • CancerPhase 3
  • Cervical carcinomaPhase 3
  • Colon carcinomaPhase 3
  • Colorectal adenocarcinomaPhase 3
  • Colorectal cancerPhase 3
  • Disease recurrencePhase 3
  • Endometrial cancerPhase 3
  • Endometrial carcinomaPhase 3
152 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3707227, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7990, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Atezolizumab

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 12 technology appraisals of Atezolizumab. 10 are current, and 8 of these recommend it for at least some patients. 2 older appraisals were replaced or withdrawn.

AppraisalNICE recommendationPublishedStatus
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA1071
Recommended19 Jun 2025Current
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)
NICE TA1047
Terminated (no company submission)12 Mar 2025Current
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
NICE TA739
Recommended27 Oct 2021Current
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
NICE TA705
Recommended2 Jun 2021Current
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
NICE TA666
Optimised16 Dec 2020Current
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
NICE TA638
Optimised1 Jul 2020Current
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
NICE TA639
Recommended1 Jul 2020Current
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)
NICE TA618
Terminated (no company submission)15 Jan 2020Current

See all 10 appraisals →

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Atezolizumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • IE
    Ireland: 3 products on the HPRA list
    Each product record links to the HPRA, which publishes the leaflet and SmPC.
  • EU
    European Union: Tecentriq
    EMA product information: package leaflet and summary of product characteristics in every EU language.
  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting7040%
  • Not yet open63%
  • Active, closed9755%
  • By invitation21%

Trials by phase

  • Phase 26738%
  • Phase 34023%
  • Phase 12615%
  • Phase 1/22011%
  • Observational95%
  • Phase 2/374%
  • Phase 432%
  • Not applicable21%
  • Early Phase 111%
01

Clinical trials of Atezolizumab

175 trials
StudyPhaseStatusLead sponsorRegisters
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06031233 · ClinicalTrials.gov ↗ · Oncology, Infusion Reaction
Phase 4 Recruiting Isala Netherlands
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 3 Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Germany, France, Spain, Italy, Austria, Japan
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
NCT04996017 · ClinicalTrials.gov ↗ · Mesotheliomas Pleural
Phase 3 Recruiting Gruppo Oncologico Italiano di Ricerca Clinica Italy
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858 · Brain Tumor, Non Small Cell Lung Cancer
Phase 3 Recruiting InSightec USA, Canada, South Korea
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285 · Cancer
Phase 3 Recruiting Hoffmann-La Roche UK, China, France, Belgium, Poland, Canada, Mexico, Japan, South Korea, Taiwan
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276 · Extensive-Stage Small Cell Lung Cancer
Phase 3 Recruiting Bristol-Myers Squibb UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355 · Extensive-stage Small-cell Lung Cancer
Phase 3 Recruiting BioNTech SE UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Japan, South Korea, Australia, Israel
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
NCT06733038 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 3 Recruiting Gruppo Oncologico del Nord-Ovest Italy
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
Phase 3 Recruiting Intergroupe Francophone de Cancerologie Thoracique France
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785 · Hepatocellular Carcinoma
Phase 3 Recruiting AstraZeneca UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Phase 3 Recruiting NRG Oncology Canada, Mexico
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695 · Non-small Cell Lung Cancer
Phase 3 Recruiting Boehringer Ingelheim UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517 · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Phase 3 Recruiting Boehringer Ingelheim Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644 · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
Phase 3 Recruiting SystImmune Inc USA, India, Germany, France, Spain, Italy, Poland, Czechia, Canada, South Korea, Australia
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999 · Small Cell Lung Cancer (SCLC)
Phase 2/3 Recruiting Pfizer USA, China, Germany, France, Spain, Italy, Japan, Taiwan, Australia
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
NCT07285850 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
Phase 2/3 Recruiting Eastern Hepatobiliary Surgery Hospital China
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)
NCT03548428 · ClinicalTrials.gov ↗ · Sarcoma, Radiosurgery
Phase 2 Recruiting Centre Antoine Lacassagne France
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
NCT03767075 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 2 Recruiting Vall d'Hebron Institute of Oncology Germany, France, Spain, Italy, Netherlands, Sweden
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
NCT04273061 · ClinicalTrials.gov ↗ · Breast Cancer, Lung Cancer, Gastrointestinal Cancer
Phase 2 Recruiting British Columbia Cancer Agency Canada
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
NCT04341181 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasms
Phase 2 Recruiting Ulrik Lassen Denmark
PLATFORM Study of Precision Medicine for Rare Tumors
NCT04423185 · ClinicalTrials.gov ↗ · Rare Tumor
Phase 2 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT04812366 · ClinicalTrials.gov ↗ · Prostate Cancer
Phase 2 Recruiting University of British Columbia Canada, Israel
Improving Public Cancer Care by Implementing Precision Medicine in Norway
NCT04817956 · ClinicalTrials.gov ↗ · Cancer Metastatic
Phase 2 Recruiting Oslo University Hospital Norway
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
NCT05332561 · ClinicalTrials.gov ↗ · Early-stage Breast Cancer
Phase 2 Recruiting German Cancer Research Center Germany
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT05528952 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 2 Recruiting Centre Hospitalier Universitaire de Besancon France
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
NCT05690048 · ClinicalTrials.gov ↗ · Immunotherapy, HCC - Hepatocellular Carcinoma
Phase 2 Recruiting Michael Dill Germany
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
NCT05733598 · Hepatocellular Carcinoma, Biliary Tract Cancer
Phase 2 Recruiting Replimune, Inc USA
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT06133062 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable
Phase 2 Recruiting Chang Gung Memorial Hospital Taiwan
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT06339424 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 2 Recruiting Chang Gung Memorial Hospital Taiwan
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
NCT06342037 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer
Phase 2 Recruiting The Netherlands Cancer Institute Netherlands
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
NCT06663098 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2 Recruiting Gruppo Oncologico Italiano di Ricerca Clinica Italy
Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
NCT06690840 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 2 Recruiting European Institute of Oncology Italy
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer
Phase 2 Recruiting Fundación GECP Spain
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174 · Small Cell Lung Cancer
Phase 2 Recruiting AbbVie USA, China, Germany, Spain, Italy, Belgium, Poland, Turkey, Japan, South Korea, Taiwan, Israel
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
Phase 2 Recruiting Peking Union Medical College Hospital China
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
NCT07235293 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 2 Recruiting Kahr Bio Australia Pty Ltd USA, Australia
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Phase 2 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
NCT07263438 · ClinicalTrials.gov ↗ · Glioblastoma, Recurrence Tumor
Phase 2 Recruiting Centre Hospitalier Universitaire Vaudois Switzerland
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
NCT07317414 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 2 Recruiting Peking Union Medical College Hospital China
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
NCT07654400 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer
Phase 2 Recruiting Biokin (Shanghai) Biopharmaceutical Co., Ltd China
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005 · Metastatic Breast Cancer
Phase 1/2 Recruiting Hoffmann-La Roche UK, USA, Germany, France, Spain, South Korea, Taiwan, Australia, Israel
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT04802759 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Phase 1/2 Recruiting Hoffmann-La Roche USA, Spain, South Korea, Australia, Israel
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
NCT04954599 · ClinicalTrials.gov ↗ · Unspecified Adult Solid Tumor, Protocol Specific
Phase 1/2 Recruiting Maastricht University Medical Center Spain, Netherlands, Belgium
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
NCT05440708 · Hepatocellular Carcinoma
Phase 1/2 Recruiting Tvardi Therapeutics, Incorporated USA
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)
Phase 1/2 Recruiting Phanes Therapeutics USA
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971 · Small Cell Lung Cancer Extensive Stage
Phase 1/2 Recruiting Genprex, Inc USA
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
NCT05765084 · ClinicalTrials.gov ↗ · Malignant Pleural Mesothelioma
Phase 1/2 Recruiting University Hospital, Antwerp Belgium
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT06157827 · ClinicalTrials.gov ↗ · Advanced Neuroendocrine Carcinoma
Phase 1/2 Recruiting Nanjing Leads Biolabs Co.,Ltd China
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
NCT06362252 · Extensive Stage-small Cell Lung Cancer
Phase 1/2 Recruiting Daiichi Sankyo USA, France, Spain, Japan
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597 · Small Cell Lung Cancer Extensive Stage
Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China, Germany, Spain, Italy, Poland, Turkey, South Korea, Israel
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933 · Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Phase 1/2 Recruiting MediLink Therapeutics (Suzhou) Co., Ltd UK, USA, France, Spain, Italy, Belgium, Poland
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895 · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
Phase 1/2 Recruiting Boehringer Ingelheim UK, USA, China, Germany, France, Spain, Netherlands, Belgium, Poland, Japan, Australia
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223 · Metastatic Colorectal Cancer
Phase 1 Recruiting Hoffmann-La Roche UK, USA, Germany, Spain, Italy, Denmark, Poland, Canada, South Korea, Taiwan, Australia
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
NCT05096715 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma
Phase 1 Recruiting Massachusetts General Hospital Israel
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
NCT05907980 · Solid Tumor
Phase 1 Recruiting Chugai Pharmaceutical USA, Japan
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
NCT06012734 · ClinicalTrials.gov ↗ · Metastatic Microsatellite-stable Colorectal Cancer
Phase 1 Recruiting The Netherlands Cancer Institute Netherlands
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069 · SCLC
Phase 1 Recruiting Zai Lab (Shanghai) Co., Ltd USA, China, Spain, Israel
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815 · Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1 Recruiting KaliVir Immunotherapeutics USA
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
NCT06478693 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 1 Recruiting Myeloid Therapeutics South Korea, Taiwan, Australia
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
NCT06505824 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Neuroendocrine Tumors
Phase 1 Recruiting Biokin (Shanghai) Biopharmaceutical Co., Ltd China
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142 · Neoplasms
Phase 1 Recruiting GlaxoSmithKline UK, USA, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Israel
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer
Phase 1 Recruiting SystImmune Inc USA
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
NCT07190833 · ClinicalTrials.gov ↗ · Treatment-Refractory Solid Tumors
Phase 1 Recruiting Bionoxx Inc South Korea
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT05713994 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable
Observational Recruiting Ze-yang Ding, MD China
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
NCT05797493 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
Observational Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS Italy
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
NCT06323382 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
Observational Recruiting Sun Yat-sen University China
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
NCT06780826 · ClinicalTrials.gov ↗ · Lung Cancer, Small Cell
Observational Recruiting Shanghai Pulmonary Hospital, Shanghai, China China
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
NCT07284121 · Lung Cancer, Hepatocellular Carcinoma
Observational Recruiting Hoffmann-La Roche UK, Spain, Italy, Belgium, Poland, Austria
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NCT05984511 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
Not applicable Recruiting Third Affiliated Hospital, Sun Yat-Sen University China
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
NCT07538128 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma
Early Phase 1 Recruiting Huashan Hospital China
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
NCT07461675 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC), Immunotherapy
Phase 3 Not yet open University of Geneva, Switzerland Switzerland
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
NCT07929051 · ClinicalTrials.gov ↗ · Advanced Cancer
Phase 3 Not yet open Boehringer Ingelheim Germany, France, Spain, Belgium, Poland, Japan
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
NCT05703997 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma
Phase 2 Not yet open Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Italy
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
NCT07774247 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)
Phase 2 Not yet open CHA University South Korea
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
NCT07093762 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Observational Not yet open Fuzhou General Hospital China
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
NCT07904494 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
Observational Not yet open Assiut University Egypt
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Cancer
Phase 4 By invitation The Methodist Hospital Research Institute Canada
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
NCT07620574 · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET)
Phase 3 By invitation Exelixis USA
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Metastatic
Phase 4 Active, closed Nikolaj Frost MD Germany
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome
Phase 3 Active, closed National Cancer Institute (NCI) Germany, Mexico, Israel
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT02997228 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Phase 3 Active, closed National Cancer Institute (NCI) Mexico
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418 · Cancer
Phase 3 Active, closed Hoffmann-La Roche UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 3 Active, closed NSABP Foundation Inc Canada, Israel
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03595592 · ClinicalTrials.gov ↗ · Invasive Breast Cancer
Phase 3 Active, closed Fondazione Michelangelo Germany, Spain, Italy, Austria
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791 · Hepatocellular Carcinoma
Phase 3 Active, closed Exelixis Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Israel
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063 · Cancer
Phase 3 Active, closed Hoffmann-La Roche USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Brazil, Mexico, Japan, South Korea, Australia, Israel
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 3 Active, closed National Cancer Institute (NCI) Norway
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT03799835 · ClinicalTrials.gov ↗ · Bladder Cancer
Phase 3 Active, closed UNICANCER France, Spain, Belgium
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002 · ClinicalTrials.gov ↗ · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Phase 3 Active, closed National Cancer Institute (NCI) Norway, Mexico, Japan, Egypt
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic
Phase 3 Active, closed Intergroupe Francophone de Cancerologie Thoracique France
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Phase 3 Active, closed National Cancer Institute (NCI) Mexico, Israel
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117 · Metastatic Prostate Cancer, Prostate Adenocarcinoma
Phase 3 Active, closed Exelixis UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594 · ClinicalTrials.gov ↗ · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma
Phase 3 Active, closed Alliance for Clinical Trials in Oncology Mexico
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 3 Active, closed Hoffmann-La Roche China, Japan
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896 · Unresectable Hepatocellular Carcinoma
Phase 3 Active, closed Hoffmann-La Roche UK, China, Germany, France, Spain, Italy, Belgium, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Israel, Egypt
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362 · Breast Cancer
Phase 3 Active, closed Hoffmann-La Roche UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05047250 · Non-Small Cell Lung Cancer
Phase 3 Active, closed Hoffmann-La Roche China
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567 · Small-Cell Lung Cancer
Phase 3 Active, closed Hoffmann-La Roche UK, USA, Germany, Spain, Italy, Belgium, Poland, Turkey, Mexico, South Korea, Taiwan
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT05112965 · ClinicalTrials.gov ↗ · Neoplasms
Phase 3 Active, closed Hoffmann-La Roche China
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141 · Small Cell Lung Carcinoma
Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940 · Colorectal Cancer
Phase 3 Active, closed Exelixis UK, USA, Germany, France, Spain, Belgium, Poland, Portugal, South Korea, Taiwan, Singapore, Australia
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886 · Hepatocellular Carcinoma
Phase 3 Active, closed Hoffmann-La Roche UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327 · ClinicalTrials.gov ↗ · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Phase 3 Active, closed Alliance for Clinical Trials in Oncology Mexico
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707 · ClinicalTrials.gov ↗ · Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Phase 2/3 Active, closed National Cancer Institute (NCI) Mexico, Israel, Egypt
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552 · Non-Small Cell Lung Cancer
Phase 2/3 Active, closed Hoffmann-La Roche USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552 · ClinicalTrials.gov ↗ · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Phase 2/3 Active, closed National Cancer Institute (NCI) Mexico
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
NCT05141721 · Colorectal Neoplasms
Phase 2/3 Active, closed Seattle Project Corporation USA
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06109272 · Hepatocellular Carcinoma
Phase 2/3 Active, closed AbbVie USA, China, France, Spain, Italy, Taiwan
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00781612 · Neoplasm Metastasis
Phase 2 Active, closed Genentech, Inc UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Czechia, Norway, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2 Active, closed The Netherlands Cancer Institute Netherlands
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
NCT02849496 · ClinicalTrials.gov ↗ · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma
Phase 2 Active, closed National Cancer Institute (NCI) Israel
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
NCT03141684 · ClinicalTrials.gov ↗ · Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Phase 2 Active, closed National Cancer Institute (NCI) Israel
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma
Phase 2 Active, closed ImmunityBio, Inc USA
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
NCT03421288 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Phase 2 Active, closed Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Germany, Switzerland
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
NCT03448835 · ClinicalTrials.gov ↗ · Stomach Cancer, Gastro Esophageal Junction Cancer
Phase 2 Active, closed The Netherlands Cancer Institute Netherlands
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
NCT03463057 · NHL, DLBCL
Phase 2 Active, closed Stichting Hemato-Oncologie voor Volwassenen Nederland Netherlands, Belgium
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
NCT03540420 · Small-cell Lung Cancer
Phase 2 Active, closed Norwegian University of Science and Technology Netherlands, Sweden, Denmark, Switzerland, Norway
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT03697850 · ClinicalTrials.gov ↗ · Bladder Cancer
Phase 2 Active, closed UNICANCER France
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT03756298 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 2 Active, closed National Cancer Center, Korea South Korea
Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
NCT03896074 · ClinicalTrials.gov ↗ · Non-small-cell Lung Cancer Patients
Phase 2 Active, closed Fondazione Ricerca Traslazionale Italy
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
NCT04017455 · ClinicalTrials.gov ↗ · Rectal Cancer
Phase 2 Active, closed The Netherlands Cancer Institute Netherlands
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation
NCT04082897 · ClinicalTrials.gov ↗ · CLL Transformation
Phase 2 Active, closed Niguarda Hospital Italy, Switzerland
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
NCT04138628 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Cancer, Metastatic
Phase 2 Active, closed Jørgen Bjerggaard Jensen Denmark
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer
NCT04186013 · ClinicalTrials.gov ↗ · Bladder Cancer
Phase 2 Active, closed Spanish Oncology Genito-Urinary Group Spain
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
NCT04302025 · Non-small Cell Lung Cancer
Phase 2 Active, closed Genentech, Inc USA
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Phase 2 Active, closed National Cancer Institute (NCI) Mexico, Israel
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
NCT04334941 · ClinicalTrials.gov ↗ · Extensive Stage Lung Small Cell Carcinoma
Phase 2 Active, closed National Cancer Institute (NCI) Mexico, Israel
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT04356729 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma
Phase 2 Active, closed F. Stephen Hodi, MD Israel
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
NCT04458922 · ClinicalTrials.gov ↗ · Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma
Phase 2 Active, closed National Cancer Institute (NCI) Canada
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
NCT04563338 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases
Phase 2 Active, closed University Health Network, Toronto Canada
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845 · Solid Tumors
Phase 2 Active, closed Hoffmann-La Roche UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel, Egypt
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
NCT04630730 · ClinicalTrials.gov ↗ · Bladder Cancer
Phase 2 Active, closed Swiss Cancer Institute Switzerland
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
NCT04722575 · ClinicalTrials.gov ↗ · Melanoma
Phase 2 Active, closed Fondazione Melanoma Onlus Italy
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
NCT04727307 · Hepatocellular Carcinoma
Phase 2 Active, closed University Hospital, Montpellier France
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
NCT04759248 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2 Active, closed SOLTI Breast Cancer Research Group Spain
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT04931342 · Ovarian Cancer
Phase 2 Active, closed Hoffmann-La Roche UK, USA, Germany, France, Spain, Italy, Switzerland, Czechia, Turkey, Canada, South Korea, Australia
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
NCT04962126 · ClinicalTrials.gov ↗ · Follicular Lymphoma
Phase 2 Active, closed Olivia Newton-John Cancer Research Institute Australia
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
NCT05009069 · Rectal Neoplasms, Rectal Cancer
Phase 2 Active, closed Hoffmann-La Roche China
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
NCT05118724 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 2 Active, closed AIO-Studien-gGmbH Germany
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
NCT05152472 · ClinicalTrials.gov ↗ · Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
Phase 2 Active, closed Centre Leon Berard France
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
NCT05174650 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma
Phase 2 Active, closed Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Germany
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489 · Extensive Stage Small Cell Lung Cancer
Phase 2 Active, closed Shanghai Henlius Biotech USA, Egypt
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
NCT05470595 · ClinicalTrials.gov ↗ · Large Cell Neuroendocrine Carcinoma of the Lung
Phase 2 Active, closed Technische Universität Dresden Germany
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692 · Urothelial Cancer
Phase 2 Active, closed Hoffmann-La Roche UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Turkey, Brazil, Mexico, South Korea, Australia
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT05781308 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Phase 2 Active, closed Intergroupe Francophone de Cancerologie Thoracique France
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
NCT05825625 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 2 Active, closed Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Germany
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326 · Adenocarcinoma, Pancreatic Ductal
Phase 2 Active, closed Genentech, Inc UK, USA, Germany, France, Spain, Netherlands, Belgium, Sweden, Canada, South Korea
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
NCT06003621 · ClinicalTrials.gov ↗ · Solid Tumor, Adult
Phase 2 Active, closed Omico Australia
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
NCT06096779 · Hepatocellular Carcinoma
Phase 2 Active, closed Genentech, Inc USA, Israel
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT04440735 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Phase 1/2 Active, closed Kahr Medical USA
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
NCT04471727 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Phase 1/2 Active, closed Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) USA
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
NCT04524871 · Advanced Liver Cancers
Phase 1/2 Active, closed Hoffmann-La Roche USA, China, France, South Korea, Taiwan, Israel
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696 · Extensive Stage Small Cell Lung Cancer
Phase 1/2 Active, closed Novartis Pharmaceuticals UK, USA, China, Germany, France, Spain, Austria, Czechia, Canada, South Korea, Singapore, Israel
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801 · ClinicalTrials.gov ↗ · Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma
Phase 1/2 Active, closed National Cancer Institute (NCI) Canada, Australia
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
NCT05300282 · ClinicalTrials.gov ↗ · Relapsed or Refractory Hodgkin's Lymphoma
Phase 1/2 Active, closed Fondazione Italiana Linfomi - ETS Italy
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer
Phase 1/2 Active, closed FBD Biologics Limited China
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07280377 · ClinicalTrials.gov ↗ · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic
Phase 1/2 Active, closed Oncolytics Biotech Germany
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
NCT02862275 · ClinicalTrials.gov ↗ · Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Phase 1 Active, closed National Cancer Institute (NCI) Canada
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960 · Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Active, closed Exelixis UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Australia
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166 · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma
Phase 1 Active, closed Exelixis UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Czechia, Australia
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Phase 1 Active, closed Amgen UK, USA, Germany, Spain, Italy, Netherlands, Belgium, Austria, Canada, Japan, South Korea, Taiwan, Australia
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874 · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Phase 1 Active, closed Genentech, Inc UK, USA, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Norway, Canada, Brazil, South Korea, Australia, Israel
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
NCT04808245 · ClinicalTrials.gov ↗ · Newly Diagnosed H3-mutated Glioma
Phase 1 Active, closed German Cancer Research Center Germany
Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
NCT05097911 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma
Phase 1 Active, closed National University Hospital, Singapore Singapore
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395 · Extensive Stage Small Cell Lung Cancer
Phase 1 Active, closed Amgen USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Canada, Japan, South Korea, Taiwan, Australia, Israel
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
NCT05546879 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 1 Active, closed University Hospital, Grenoble France
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004 · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC
Phase 1 Active, closed Genentech, Inc USA, Spain, Netherlands, Belgium, Canada, South Korea, Taiwan, Australia
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
NCT05595460 · SCLC,Extensive Stage
Phase 1 Active, closed RayzeBio, Inc USA
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
NCT05878691 · Advanced Solid Tumor, Lymphoma
Phase 1 Active, closed Glenmark Specialty S.A USA, India
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441 · Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Phase 1 Active, closed Genentech, Inc UK, USA, Canada, Singapore, Australia
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
NCT06077500 · Small Cell Lung Carcinoma (SCLC)
Phase 1 Active, closed Boehringer Ingelheim USA, Germany, France, Spain, Belgium, Poland, Switzerland, Japan
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
NCT06496568 · PIK3CA-Mutated Cancers
Phase 1 Active, closed Hoffmann-La Roche USA, Canada, South Korea
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
NCT05525858 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
Observational Active, closed Seoul National University Bundang Hospital South Korea
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT06117891 · Unresectable Hepatocellular Carcinoma
Observational Active, closed Bayer USA, China, France, Spain, Italy, Brazil, South Korea, Taiwan
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
NCT04180072 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular
Not applicable Active, closed National Health Research Institutes, Taiwan China, Taiwan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Atezolizumab in the EU trials register (CTIS)

5 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Atezolizumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

StudyPhaseStatusSponsorCountries
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
2025-520565-51-00 · Neoplasms
Phase 3 Ongoing Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A Ireland + 19 more
Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity
2026-525397-19-00 · CTIS ↗ · Neoplasms
Phase 1 Authorised Heinrich-Heine-Universitaet Duesseldorf Germany
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”
2026-525268-16-00 · CTIS ↗ · Neoplasms
Phase 3 Authorised Universita' Degli Studi Di Torino Italy
A Phase Ib/II, open-label, safety and tolerability trial of obrixtamig in combination with ZL-1310 in patients with poorly differentiated NEC
2026-525634-27-00 · CTIS ↗ · Neoplasms
Phase 1 Ongoing Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A Poland, France, Belgium + 3 more
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
2026-525898-39-00 · Neoplasms
Phase 3 Authorised Azienda Sanitaria Locale Napoli 1 Centro Italy
03

Atezolizumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

3 single-substance products containing Atezolizumab on the HPRA medicines list.

All 3 Irish products →

Supply shortages

No entry for Atezolizumab in the EMA, FDA or German BfArM shortage lists we track.

Recent approvals

  • TecentriqFDA · 18 May 2016 · Biologic (BLA) · Genentech Inc
04

Conditions studied with Atezolizumab

209 conditions
All 209 conditions
Condition (as registered)Trials
Hepatocellular Carcinoma19
Colorectal Cancer6
Non-Small Cell Lung Cancer5
Cancer5
Small Cell Lung Cancer5
Non Small Cell Lung Cancer5
Bladder Cancer5
Breast Cancer4
Advanced Solid Tumor4
Stage II Lung Cancer AJCC v84
Small Cell Lung Cancer (SCLC)3
Unresectable Hepatocellular Carcinoma3
Extensive Stage Small Cell Lung Cancer3
Non-small Cell Lung Cancer3
Neoplasms3
Small Cell Lung Cancer Extensive Stage3
HCC - Hepatocellular Carcinoma3
Advanced Hepatocellular Carcinoma3
Triple Negative Breast Cancer3
Small Cell Lung Carcinoma2
Renal Cell Carcinoma2
Advanced Solid Tumors2
Small-Cell Lung Cancer2
Extensive-stage Small-cell Lung Cancer2
Metastatic Breast Cancer2
Urothelial Carcinoma2
Solid Tumor2
Melanoma2
Head and Neck Squamous Cell Carcinoma2
Solid Tumor, Adult2
Small-cell Lung Cancer2
Hepatocellular Carcinoma Non-resectable2
Rectal Cancer2
Immunotherapy2
Stage I Lung Cancer AJCC v82
Stage III Lung Cancer AJCC v82
Lung Non-Small Cell Carcinoma2
Hepatocellular Carcinoma (HCC)2
Extensive-stage Small Cell Lung Cancer (ES-SCLC)1
Urothelial Cancer1
Locally Advanced Solid Tumors1
Recurrent Solid Tumors1
Metastatic Solid Tumors1
Neoplasm Malignant1
Hormone Receptor Positive Breast Carcinoma1
Metastatic Castration-resistant Prostate Cancer1
Metastatic Prostate Cancer1
Prostate Adenocarcinoma1
Solid Tumors1
Neoplasm Metastasis1
Lung Cancer, Hepatocellular Carcinoma1
Ovarian Cancer1
Kirsten Rat Sarcoma (KRAS) pG12C Mutation1
Metastatic Colorectal Cancer1
Adenocarcinoma, Pancreatic Ductal1
Extensive-Stage Small Cell Lung Cancer1
Castration-resistant Prostate Cancer1
Large Cell Neuroendocrine Lung Carcinoma1
Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology1
Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology1
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma1
Large Cell Neuroendocrine Cancer (LCNEC)1
Neuroendocrine Prostate Cancer (NEPC)1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)1
Locally Advanced or Metastatic Solid Tumors1
NSCLC1
HNSCC1
Brain Tumor1
SCLC,Extensive Stage1
Colorectal Neoplasms1
SCLC1
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1
Renal Cell Carcinoma (RCC)1
Pancreatic Neuroendocrine Tumors (pNET)1
Extra-Pancreatic NET (epNET)1
Extensive Stage-small Cell Lung Cancer1
Advanced Liver Cancers1
Biliary Tract Cancer1
PIK3CA-Mutated Cancers1
Microsatellite Stable Colorectal Cancer1
Cervical Cancer1
Small Cell Lung Carcinoma (SCLC)1
Small Cell Carcinoma1
Sclc1
Lymphoma1
Neuroendocrine Carcinoma1
Carcinoma, Hepatocellular1
Recurrent Glioblastoma1
Rare Tumor1
Advanced Neuroendocrine Carcinoma1
Rectal Neoplasms1
Solid Cancer1
Anti-PD1/PDL1 Antibody1
Bevacizumab1
Hepatic Portal Vein Tumor Invasion1
Tumor Thrombus1
Resectable Hepatocellular Carcinoma With High Risk of Recurrence1
Lung Cancer, Small Cell1
Advanced Cancer1
Large Cell Neuroendocrine Carcinoma of the Lung1
Invasive Breast Cancer1
Newly Diagnosed H3-mutated Glioma1
Non-Small Cell Lung Cancer Metastatic1
Early-stage Breast Cancer1
Intrahepatic Cholangiocarcinoma1
Anal Cancer Metastatic1
Squamous Cell Carcinoma of the Anus Stage Unspecified1
Pancreatic Cancer Metastatic1
Unresectable Pancreatic Carcinoma1
Gastric Cancer1
Gastroesophageal Junction Adenocarcinoma1
Colon Adenocarcinoma1
DNA Repair Disorder1
Lynch Syndrome1
Stage III Colon Cancer AJCC v81
Sarcoma1
Radiosurgery1
Unresectable Gastrointestinal Stromal Tumor (GIST)1
Locally Advanced Gastrointestinal Stromal Tumor (GIST)1
Metastatic Gastrointestinal Stromal Tumor1
Advanced Non Small Cell Lung Cancer1
MET Exon 14 Mutation1
Non Small Cell Lung Cancer Metastatic1
Unspecified Adult Solid Tumor, Protocol Specific1
Stage IIIA Lung Cancer1
Stage IIIB Lung Cancer1
Relapsed or Refractory Hodgkin's Lymphoma1
CLL Transformation1
Non-small-cell Lung Cancer Patients1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
Mesotheliomas Pleural1
Stomach Cancer1
Gastro Esophageal Junction Cancer1
NHL1
DLBCL1
Metastatic Microsatellite-stable Colorectal Cancer1
Oncology1
Infusion Reaction1
Malignant Pleural Mesothelioma1
Tumors1
Neoplasia1
Bladder Cancer, Metastatic1
Hepato Cellular Carcinoma (HCC)1
Glioblastoma1
Recurrence Tumor1
Limited Stage Lung Small Cell Carcinoma1
Bladder Urothelial Carcinoma1
Muscle Invasive Bladder Carcinoma1
Stage II Bladder Cancer AJCC v81
Stage IIIA Bladder Cancer AJCC v81
Cancer Metastatic1
Prostate Cancer1
Hematopoietic and Lymphoid Cell Neoplasm1
Metastatic Malignant Solid Neoplasm1
Unresectable Malignant Solid Neoplasm1
Atypical Teratoid/Rhabdoid Tumor1
Epithelioid Sarcoma1
Kidney Medullary Carcinoma1
Malignant Solid Neoplasm1
Non-small Cell Lung Cancer Metastatic1
Liver Metastases1
Central Chondrosarcoma, Grade 21
Central Chondrosarcoma, Grade 31
Dedifferentiated Chondrosarcoma1
Metastatic Clear Cell Sarcoma of Soft Tissue1
Stage III Hepatocellular Carcinoma AJCC v81
Stage IV Hepatocellular Carcinoma AJCC v81
Lung Cancer1
Gastrointestinal Cancer1
Genitourinary Cancer1
Hepatocellular Cancer1
Extensive Stage Lung Small Cell Carcinoma1
Metastatic Colorectal Adenocarcinoma1
Stage IV Colorectal Cancer AJCC v71
Locally Advanced Bladder Urothelial Carcinoma1
Locally Advanced Renal Pelvis Urothelial Carcinoma1
Locally Advanced Ureter Urothelial Carcinoma1
Locally Advanced Urethral Urothelial Carcinoma1
Fallopian Tube High Grade Serous Adenocarcinoma1
Ovarian High Grade Serous Adenocarcinoma1
Ovarian Seromucinous Carcinoma1
Primary Peritoneal High Grade Serous Adenocarcinoma1
Resectable Lung Non-Small Cell Carcinoma1
Stage IIIA Lung Cancer AJCC v81
Stage IIIB Lung Cancer AJCC v81
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81
Metastatic Head and Neck Squamous Cell Carcinoma1
Metastatic Hypopharyngeal Squamous Cell Carcinoma1
Metastatic Laryngeal Squamous Cell Carcinoma1
Treatment-Refractory Solid Tumors1
Metastatic Cancer1
Follicular Lymphoma1
Anatomic Stage III Breast Cancer AJCC v81
Anatomic Stage IV Breast Cancer AJCC v81
Locally Advanced Unresectable Breast Carcinoma1
Metastatic Breast Carcinoma1
Metastatic Alveolar Soft Part Sarcoma1
Unresectable Alveolar Soft Part Sarcoma1
Clinical Stage III Cutaneous Melanoma AJCC v81
Stage IV Melanoma1
Unresectable Stage III Cutaneous Melanoma1
Unresectable Stage IV Cutaneous Melanoma1
Hepatocellular Carcinoma Non-Resectable1
Hepatocellular Carcinoma Metastatic1
Small Cell Lung Cancer Metastatic or Locally Advanced1
Neuroendocrine Cancer1
Metastatic Neuroendocrine Prostate Cancer1
Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma1
Neuroendocrine Tumors1
05

Sponsors

lead sponsor per trial
Lead sponsorTrials
Hoffmann-La Roche21
National Cancer Institute (NCI)14
Genentech, Inc7
Exelixis6
Boehringer Ingelheim5
The Netherlands Cancer Institute5
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest4
Intergroupe Francophone de Cancerologie Thoracique3
Merck Sharp & Dohme LLC2
Amgen2
AbbVie2
SystImmune Inc2
Biokin (Shanghai) Biopharmaceutical Co., Ltd2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2
Peking Union Medical College Hospital2

+ 91 more sponsors in the trial list above.

06

By country register

RegisterTrialsRecruiting
Clinical trials in USA6426
Clinical trials in Spain5322
Clinical trials in Germany4916
Clinical trials in France4918
Clinical trials in Italy4720
Clinical trials in China4524
Clinical trials in South Korea4316
Clinical trials in Canada3612
Clinical trials in Australia3513
Clinical trials in Israel3310
Clinical trials in Belgium3310
Clinical trials in UK3212
Clinical trials in Taiwan3012
Clinical trials in Poland2812
Clinical trials in Japan2813
Clinical trials in Netherlands2611
Clinical trials in Mexico265
Clinical trials in Turkey177
Clinical trials in Switzerland173
Clinical trials in Brazil174
Clinical trials in Austria145
Clinical trials in Czechia123
Clinical trials in Singapore122
Clinical trials in Denmark113
Clinical trials in Portugal92
Clinical trials in Norway72
Clinical trials in Sweden63
Clinical trials in Egypt60
Clinical trials in India53
Clinical trials in Ireland31
EU register (CTIS)5—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

07

Related compounds

08

Questions about Atezolizumab trials

How many clinical trials are testing Atezolizumab?

175 current trials in our USA, Spain, Germany, France, Italy, China, South Korea, Canada, Australia, Israel, Belgium, UK, Taiwan, Poland, Japan, Netherlands, Mexico, Turkey, Switzerland, Brazil, Austria, Czechia, Singapore, Denmark, Portugal, Norway, Sweden, Egypt, India and Ireland registers name Atezolizumab (also registered as RO5541267) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.

Are Atezolizumab trials recruiting patients?

Yes. 70 of the 175 trials are recruiting: 26 with sites in USA, 22 with sites in Spain, 16 with sites in Germany, 18 with sites in France, 20 with sites in Italy, 24 with sites in China, 16 with sites in South Korea, 12 with sites in Canada, 13 with sites in Australia, 10 with sites in Israel, 10 with sites in Belgium, 12 with sites in UK, 12 with sites in Taiwan, 12 with sites in Poland, 13 with sites in Japan, 11 with sites in Netherlands, 5 with sites in Mexico, 7 with sites in Turkey, 3 with sites in Switzerland, 4 with sites in Brazil, 5 with sites in Austria, 3 with sites in Czechia, 2 with sites in Singapore, 3 with sites in Denmark, 2 with sites in Portugal, 2 with sites in Norway, 3 with sites in Sweden, 3 with sites in India and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Atezolizumab clinical trials?

Hoffmann-La Roche (21), National Cancer Institute (NCI) (14), Genentech, Inc (7) and Exelixis (6), among 106 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Atezolizumab clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Atezolizumab licensed in Ireland?

Yes. The HPRA medicines list includes 3 single-substance products containing Atezolizumab, for example Tecentriq 1200 mg concentrate for solution for infusion (Roche Registration GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Atezolizumab shortage?

Not in the lists we track: Atezolizumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Atezolizumab works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Atezolizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Atezolizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.